Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03939455 · ClinicalTrials.gov registry record · NA
Mobile Augmented Screening Tool to Increase Adolescent HIV Testing and Linkage to Care
A NA study, sponsored by New York University.
- Completed
- Registry status
- NA
- Development phase
- 295
- Enrollment target
NCT03939455: Completed NA study, sponsored by New York University.
NCT03939455 is a NA study that has completed, run by New York University. The registered enrollment target is 295 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03939455, a NA study, has completed, sponsored by New York University.
- COMPLETED
- Registry status
- NA
- Development phase
- 295 participants
- Enrollment target
Study Summary
Because adolescents and young adults face markedly increased HIV risk yet frequently do not test, we propose to complete the Mobile Augmented Screening (MAS) tool designed to increase HIV testing, and to facilitate linkage to care and ongoing prevention education. This tool will help clinicians address undiagnosed youth HIV, and enable young patients to receive much needed treatment and avoid unknowingly transmitting infection. Our product is designed to help existing program staff reach an increased number of clients; and to improve public health by encouraging reluctant young patients to accept important HIV testing and care they may otherwise decline.
Primary Outcome
The main outcome is participant HIV testing. We will measure whether the participant accepts an HIV test when offered. Possible outcomes are Yes or No.
Interventions
- OTHER Mobile Augmented Screening tool
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 295 participants |
| Start Date | 2019-07-22 |
| Est. Completion | 2020-06-01 |
| Phase | NA |
What the finished NCT03939455 record still lists
NCT03939455 is an interventional study that assigns participants to a tested intervention. The registered 295 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (79% lower).
The record links to 0 conditions, and to 1 intervention - of which Mobile Augmented Screening tool is the first listed.
NCT03939455 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03939455 about?
NCT03939455 is a clinical study titled "Mobile Augmented Screening Tool to Increase Adolescent HIV Testing and Linkage to Care". Because adolescents and young adults face markedly increased HIV risk yet frequently do not test, we propose to complete the Mobile Augmented Screening (MAS) tool designed to increase HIV testing, and to facilitate linkage to care and ongoing prevention education. This tool will help clinicians addr...
What is the current status of trial NCT03939455?
This trial is currently completed. It is a NA study. The enrollment target is 295 participants. The study started on 2019-07-22. Estimated completion is 2020-06-01.
What interventions are being tested in trial NCT03939455?
The interventions under investigation include: Mobile Augmented Screening tool (OTHER).
Who is sponsoring clinical trial NCT03939455?
This trial is sponsored by New York University, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03939455's enrollment target sits among peer trials
295 373rd of 2000 higher than 1,628 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05201781 · 295 participants · Phase 4
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- NCT06004245 · 295 participants · Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
- NCT06494111 · 295 participants · Phase 2
Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE)
- NCT07020221 · 295 participants · Phase 1
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI